| Name | Title | Contact Details |
|---|---|---|
Luke Gordon |
Vice President of Network Development | Profile |
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
Visit the orthopedic surgeons and spine specialists at Envision Ortho, serving patients in Atlanta, Augusta, and Savannah, Georgia.
CutisPharma is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Berkeley Premium Nutraceuticals currently offers six supplements to address issues including sexual health, fatigue, night vision, and cardiovascular health. The Company is also investigating new formulas to assist with other concerns, including prostate
Sonovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.